Description

Basilea Pharmaceutica AG is a revenue-generating biopharmaceutical company dedicated to developing innovative products to meet critical medical needs in both cancer treatment (oncology) and the fight against infections (anti-infectives). The company offers Cresemba, an antifungal medication available in both intravenous and oral forms, used to treat invasive aspergillosis and mucormycosis in the United States and the European Union. Cresemba is also progressing through Phase III clinical trials in Japan for additional invasive fungal infections. Another key product is Zevtera, an antibiotic utilized for treating community-acquired and hospital-acquired pneumonia. Zevtera is also currently in Phase III clinical trials for addressing acute bacterial skin and skin structure infections, as well as bacteremia caused by Staphylococcus aureus. Basilea's development pipeline further includes Derazantinib, a small molecule inhibitor, which is in Phase 2 clinical trials for bile duct cancer, and Phase 1/2 clinical trials for bladder and stomach cancers. They are also advancing Lisavanbulin, a compound designed to act as a tumor checkpoint controller. Founded in 2000, Basilea Pharmaceutica AG operates from its headquarters in Basel, Switzerland.